Vitamin D supplement fails to lower cholesterol in short term
September 04, 2012
- Correcting low vitamin D levels with high doses of vitamin D3 supplements failed to improve cholesterol levels at two months and worsened the cholesterol profile for some people.
- These results contradict the association between higher vitamin D levels and healthier cholesterol levels.
EMBARGOED UNTIL 3 pm CT/4 pm ET, Tuesday, September 4, 2012
DALLAS, Sept. 4, 2012 — Taking vitamin D supplements to compensate for vitamin D deficiency didn’t improve cholesterol — at least in the short term, according to new research in Arteriosclerosis, Thrombosis and Vascular Biology, an American Heart Association journal.
Researchers studied 151 people with vitamin D deficiency who received either a mega-dose (50,000 internationals units) of vitamin D3 or placebo weekly for eight weeks. Participants’ cholesterol levels were measured before and after treatment.
Correcting vitamin D deficiencies with high doses of oral vitamin D supplements did not change cholesterol levels, researchers found. This was despite effectively increasing vitamin D to recommended levels. Vitamin D levels nearly tripled in the group that received actual supplements, but were unchanged in the placebo group.
“Our study challenges the notion that vitamin D repletion improves cholesterol levels” said Manish Ponda, M.D., M.S., study lead author and assistant professor of clinical investigation in Dr. Jan Breslow’s laboratory of biochemical genetics and metabolism at The Rockefeller University in New York, N.Y. “These clinical trial results confirm those from a recent data mining study.”
The researchers also tested the effect of vitamin D supplementation on more sophisticated biomarker measures of cholesterol, such as particle size and number. “These measures of cholesterol, which are not used in routine clinical practice, also did not change in response to vitamin D therapy,” Ponda said.
As expected, replenishing subjects with high-dose supplements of oral vitamin D decreased parathyroid hormone levels and increased calcium levels — physical functional changes that were linked to participants’ increase in low-density lipoprotein (LDL, bad cholesterol).
“For example, participants receiving vitamin D who had an increase in calcium levels experienced a 7 percent increase in LDL cholesterol, while those whose calcium levels fell or did not change had a 5 percent decrease in LDL cholesterol,” Ponda said.
The study questions the use of vitamin D supplements to improve cholesterol, Ponda said. While the dose of vitamin D in this study was high, it was appropriate for correcting a vitamin D deficiency over an eight week period.
However, longer-term studies on the impact of the changes in LDL cholesterol as a result of high dose vitamin D supplementation are needed to make stronger recommendations. And questions remain about whether increasing vitamin D levels with exposure to sunlight, the predominant natural source, would have a different effect than with high-dose oral supplements.
To address these issues, Ponda and Breslow will begin another clinical trial this fall, comparing the effect of oral vitamin D to ultraviolet light exposure with a longer follow-up period.
Co-authors are Kathleen Dowd, R.N.; Dennis Finkielstein, M.D.; Peter R. Holt, M.D.; and Jan L. Breslow, M.D. Author disclosures and sources of funding are on the manuscript.
Visit the American Heart Association for more information on other Vitamin and Mineral Supplements .
For the latest heart news, follow us on twitter: @HeartNews .
For science updates from the Arteriosclerosis, Thrombosis and Vascular Biology journal, follow @atvbahajournals .
Statements and conclusions of study authors published in American Heart Association scientific journals are solely those of the study authors and do not necessarily reflect the association’s policy or position. The association makes no representation or guarantee as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at www.heart.org/corporatefunding .
Additional resources are available in the right column.
For media inquiries: (214) 706-1173
Karen Astle: (214) 706-1392; Karen.Astle@heart.org
Bridgette McNeill: (214) 706-1135; Bridgette.McNeill@heart.org
Julie Del Barto (broadcast): (214) 706-1330; Julie.DelBarto@heart.org
For public inquiries: (800) AHA-USA1 (242-8721)